Please use this identifier to cite or link to this item:
https://hdl.handle.net/11147/12055
Title: | Changes in molecular biology of chronic myeloid leukemia in tyrosine kinase inhibitor era | Authors: | Cömert, Melda Baran, Yusuf Saydam, Güray Ege Üniversitesi Izmir Institute of Technology Ege Üniversitesi |
Keywords: | Chronic myeloid leukemia Moleculer biology Imatinib mesylate |
Issue Date: | 2013 | Publisher: | e-Century Publishing Corporation | Abstract: | Chronic myeloid leukemia (CML) is a clonal myeloproliferative disease characterized by a reciprocal translocation between long arms of chromosomes 9 and 22 t(9; 22) that generates the BCR-ABL fusion gene. If left untreated, newly diagnosed chronic phase CML patients finally progress to accelerated and blastic phase. After the introduction of tyrosine kinase inhibitors (TKIs), treatment strategies of CML changed dramatically. However, the development of resistance to TKIs started to create problems over time. In this review, the current information about CML biology before and after imatinib mesylate treatment is summarized. | URI: | https://hdl.handle.net/11147/12055 |
Appears in Collections: | Molecular Biology and Genetics / Moleküler Biyoloji ve Genetik WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
ajbr0003-0191.pdf | Review Article | 529.06 kB | Adobe PDF | View/Open |
CORE Recommender
WEB OF SCIENCETM
Citations
13
checked on Jun 17, 2023
Page view(s)
46
checked on Dec 4, 2023
Download(s)
4
checked on Dec 4, 2023
Google ScholarTM
Check
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.